Table 1.

In vitro efficacy of MC3343 and 5azadC in relation to the basal level of DNMTs expression in osteosarcoma cell lines

IC50a, μmol/L
Cell lineMC33435azadCDNMT1bDNMT3abDNMT3bb
Saos-25.6 ± 1.60.7 ± 0.10.50 ± 0.041.02 ± 0.040.39 ± 0.08
IOR/OS145.3 ± 0.2>300.47 ± 0.050.81 ± 0.010.60 ± 0.11
MG-636.1 ± 0.70.23 ± 0.21.05 ± 0.130.72 ± 0.210.39 ± 0.14
IOR/OS98.6 ± 1.56.6 ± 3.90.38 ± 0.140.33 ± 0.190.23 ± 0.10
IOR/OS107.7 ± 3.10.9 ± 0.60.25 ± 0.080.31 ± 0.120.35 ± 0.23
U-2 OS11.8 ± 2.50.7 ± 0.20.17 ± 0.170.13 ± 0.160.72 ± 0.10
IOR/OS2014.5 ± 2.113.3 ± 3.50.20 ± 0.080.20 ± 0.090.51 ± 0.15
IOR/SARG5.1 ± 0.25.5 ± 0.80.59 ± 0.032.07 ± 0.041.28 ± 0.52
PDX-OS#1-C4c6.3 ± 0.40.5 ± 0.30.54 ± 0.170.32 ± 0.100.17 ± 0.19
PDX-OS#2-C2c6.1 ± 1.615.4 ± 1.60.47 ± 0.101.47 ± 0.120.65 ± 0.12
  • aCells were exposed to increasing concentrations of MC3343 or 5azadC for 96 hours. Data represent the mean ± SE of three independent experiments. IC50 = drug concentration inducing 50% of growth inhibition with respect to the control (untreated cells).

  • bDNMT expression values are indicated as densitometry records (normalized to ACTIN signals: OD*mm2/OD*mm2 ACTIN) ± SE.

  • cPDX-OS#1-C4 and PDX-OS#2-C2 indicated cell lines obtained from the fourth or second passage in the mice of PDX-OS#1 and PDX-OS#2, respectively.